ClinTec International expands US capabilities with the launch of New York office and senior Business Operations appointment
The expansion of US based operations through the launch of American headquarters, together with Susan Pavone’s appointment, will enable ClinTec to offer prospective US clients the chance to access global clinical research capabilities through a single partner. In the current economic climate, US life science and pharmaceutical companies are struggling to find medium sized global CROs capable of facilitating global clinical research needs. ClinTec has implemented a differentiated solution to mid-market competitors which combines all developed and emerging markets into a single global research platform.
President & CEO of ClinTec International, Dr Rabinder Buttar, commented: “We have established a strong presence in the international marketplace by placing expert clinical research staff in all key emerging, and established markets. The pharmaceutical industry is currently searching for new ways of working and delivering global solutions. ClinTec’s ability to harness global strength, coupled with local, on the ground expertise, will be of great value to US pharmaceutical companies. Our new Associate Director of (US) Operations, Susan Pavone, has extensive knowledge of international clinical research and the new US facilities will prove an invaluable asset to American companies looking to tap into our globalised resources and expertise. Susan has over two decades of industry experience, including eight years of successfully managing the business operations of Pfizer’s internal CRO, and her reputation for matching internal credibility and acceptance of solutions to client needs, is second to none.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.